Chlamydia Antibody Panel, IgG by IFA
0065139
Ordering Recommendation
 
Mnemonic
CHLAM G
Methodology
Semi-Quantitative Indirect Fluorescent Antibody
Performed
Mon-Sat
Reported
1-3 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Plain red or serum separator tube.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as acute or convalescent.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Contaminated, hemolyzed, or hyperlipemic sera.  
Remarks
  
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)  
Reference Interval
 < 1:64  C. trachomatis IgG. 
< 1:64  C. pneumoniae IgG.
<
1:64  C. psittaci IgG.  
Interpretive Data
The Chlamydia antibody test contains both species-and genus-specific antigens, and serological cross-reactions may be seen in both acute and convalescent samples (less than 1:128). A C. pneumoniae-specific reaction will exhibit titers twofold or greater than titers observed with C. trachomatis or C. psittaci serology. Any IgG titer may indicate past exposure to that particular species. IgG titers in recently infected individuals are typically greater than or equal to 1:512.

The Chlamydia microimmunofluorescent assay slides utilize C. psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. The LGV strains of C. trachomatis are not included in this assay.

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
 
Note
In adult populations, the prevalence of antibody titers indicative of exposure to the organism ranges from 50-78%.
CPT Code(s)
86631 x3
Components
Component Test Code*Component Chart Name
0065104C. pneumoniae IgG Titer
0065106C. trachomatis IgG Titer
0065107C. psittaci IgG Titer
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chlamydia IgG Ab
  • CT IgG Ab